The primary function of the immune system is to protect the body from infection by identifying and removing pathogens. A complex system, involving many individual cell populations, the immune system utilizes a range of mechanisms for the identification and subsequent removal of pathogens and other non-self material such as tumor cells. Due to the efficiency of the immune system, a range of control mechanisms serve to ensure that the potentially damaging effects of these killing mechanisms are directed specifically at pathogens, and resolved once the pathogen has been eliminated. Some of these control mechanisms utilize inhibitory pathways which mediate a negative signal to activated immune cells, instructing them to switch off. This is an important method of restricting an immune response to the period of infection only, enabling it to revert to baseline when the pathogen has been eliminated, and defects in this system can lead to hypersensitivity or autoimmune disease. It is now known that tumors exploit this system to prevent immune attack by upregulating expression of these inhibitory or ‘checkpoint’ markers to dampen the anti-tumor immune response.
Recently, this has become an area of interest for oncology. By blocking the negative signals mediated by checkpoint markers, and effectively taking the brakes off the immune system, increased anti-tumor activity can be induced. However, the complex nature of the immune system also means that any changes to its overall function can potentially lead to negative consequences, and a thorough understanding of the biology mediated by each checkpoint inhibitor product is essential in order to fully assess the risk of any unwanted effects.
Kirsty Harper, PhD, MSc, BSc, Head of Biologics, Envigo
Kirsty leads the UK Biologics team, a role she has held since October 2017, having joined Envigo in June 2013. Throughout her time with the company she has supported customers by designing safety studies and non-clinical development programs for biologics in response to specific requests as well as providing scientific support and advice. Prior to this, she was employed as Principal Scientist at Oxford Immunotec Ltd, where she was responsible for pipeline product development projects and the provision of immunological advice and expertise.
Kirsty obtained her PhD in Immunology from the University of Bristol in 2005, after which she completed a post-doctoral position investigating peptide therapy as a potential treatment for autoimmune disease. She obtained her BSc and MSc degrees in Microbiology at Massey University in New Zealand and worked at the Malaghan Institute where she conducted basic research in autoimmune disease before emigrating to the UK.Message Presenter
Who Should Attend?
Chief Medical Officers, Chief Scientific Officers, plus senior level professionals from:
- Vaccine Developers
- Biopharmaceutical Developers
- Immune Profiling Laboratories
Involved in the following fields:
- Personal Medicine
- Translational Medicine
- Immunotherapies OR Immunotherapy
What You Will Learn
- How the immune system is structured and functions in a normal situation
- How tolerance mechanisms ensure that the delicate balance between effective recognition and killing of pathogens, and the prevention of damage to the individual is maintained
- The role of checkpoint markers in the normal immune response and why they are attractive targets for the treatment of oncology indications
- Non-clinical safety assessment strategies for checkpoint inhibitor (CPI) products
Envigo provides mission-critical products and research services for pharmaceutical, crop protection, and chemical companies as well as universities, governments, and other research organizations. Our company is founded on the principle that research partnerships depend on unmatched expertise, unwavering dedication to customer service and shared goals. Envigo is committed to helping customers realize the full potential of their products and research which contribute to enhancing the lives of people and animals as well as protecting the environment.
With over 3,300+ employees serving over 65 countries with a network of more than 25 operating facilities worldwide, Envigo provides comprehensive scientific expertise and a full service offering in non-clinical research and development, research models and services, regulatory consulting, and analytical support to our customers. Envigo is a privately held global company with corporate headquarters in New Jersey.